Analysts Offer Predictions for RLAY FY2027 Earnings

Posted by Geri Gentry on Aug 21st, 2026

Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) – Equities researchers at HC Wainwright issued their FY2027 EPS estimates for shares of Relay Therapeutics in a research report issued on Thursday, August 20th. HC Wainwright analyst R. Burns anticipates that the company will earn ($1.60) per share for the year. HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.60) per share.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million.

Several other analysts have also issued reports on the company. Guggenheim restated a “buy” rating on shares of Relay Therapeutics in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Monday, July 6th. Citizens Jmp increased their price target on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Monday, August 10th. Oppenheimer lifted their price objective on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Finally, Wells Fargo & Company boosted their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.92.

Get Our Latest Stock Analysis on Relay Therapeutics

Relay Therapeutics Trading Down 5.0%

Relay Therapeutics stock opened at $19.70 on Friday. The business’s 50 day simple moving average is $18.77 and its 200 day simple moving average is $14.32. Relay Therapeutics has a 12 month low of $3.31 and a 12 month high of $21.27. The company has a market cap of $4.32 billion, a price-to-earnings ratio of -12.55 and a beta of 1.69.

Hedge Funds Weigh In On Relay Therapeutics

A number of large investors have recently modified their holdings of RLAY. AQR Capital Management LLC grew its stake in Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after acquiring an additional 38,812 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Relay Therapeutics by 6.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after acquiring an additional 5,238 shares during the period. Millennium Management LLC lifted its stake in Relay Therapeutics by 14.6% in the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Relay Therapeutics in the 1st quarter worth approximately $53,000. Finally, Woodline Partners LP boosted its holdings in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock valued at $3,979,000 after purchasing an additional 1,241,657 shares during the period. 96.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $16.97, for a total transaction of $3,176,156.11. Following the sale, the chief financial officer directly owned 177,461 shares in the company, valued at approximately $3,011,513.17. The trade was a 51.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Donald A. Bergstrom sold 93,456 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $16.94, for a total value of $1,583,144.64. Following the sale, the insider directly owned 418,557 shares in the company, valued at $7,090,355.58. This trade represents a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 409,639 shares of company stock valued at $7,233,399 in the last ninety days. 5.04% of the stock is owned by company insiders.

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.